Why the study?
Important studies investigating the effect and safety of anakinra in recurrent pericarditis were recently published, prompting an evaluation of the current evidence.
Does anakinra improve outcomes in patients with refractory recurrent pericarditis?
Does anakinra improve outcomes in patients with refractory recurrent pericarditis?
This review summarizes the current evidence regarding the clinical use, effectiveness, and safety of anakinra for refractory recurrent pericarditis.
Answers are grounded in this paper and cite their sources.
May support anakinra in refractory recurrent pericarditis; leaves open need for randomized confirmation of efficacy and safety.
Anakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.
No takes yet. Share an insight, caveat, or question.
Correia et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: